Effect of early dexamethasone on outcomes of COVID-19: A quasi-experimental study using propensity score matching

WANG-DA LIUJANN-TAY WANGShih, Ming-ChiehMing-ChiehShihChen, Kai-HsiangKai-HsiangChenHuang, Szu-TingSzu-TingHuangHuang, Chun-FuChun-FuHuangChang, Tien-HaoTien-HaoChangMING-JUI TSAIKuo, Po-HsienPo-HsienKuoYeh, Yi-ChenYi-ChenYehTsai, Wan-ChenWan-ChenTsaiPan, Mei-YanMei-YanPanLi, Guei-ChiGuei-ChiLiChen, Yi-JieYi-JieChenKUAN-YIN LINYU-SHAN HUANGARISTINE CHENGPAO-YU CHENSUNG-CHING PANHSIN-YUN SUNSHIH-CHI KUSUI-YUAN CHANGWANG-HUEI SHENGCHI-TAI FANGCHIEN-CHING HUNGYEE-CHUN CHENYI-LWUN HOMING-SHIANG WUSHAN-CHWEN CHANG2024-03-082024-03-082024-02-1716841182https://scholars.lib.ntu.edu.tw/handle/123456789/640584https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186171764&doi=10.1016%2fj.jmii.2024.02.002&partnerID=40&md5=9d3f16fd7d4cd9926fd49ed8613fcf08The RECOVERY trial demonstrated that the use of dexamethasone is associated with a 36% lower 28-day mortality in hospitalized patients with COVID-19 on invasive mechanical ventilation. Nevertheless, the optimal timing to start dexamethasone remains uncertain.enCoronavirus; Corticosteroid; SARS-CoV-2; Timing; Viral shedding[SDGs]SDG3Effect of early dexamethasone on outcomes of COVID-19: A quasi-experimental study using propensity score matchingjournal article10.1016/j.jmii.2024.02.002384020712-s2.0-85186171764